Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

University of Arizona

Status: Completed

Conditions: Coccidioidomycosis; Rheumatoid Arthritis

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00796809

07-0930-04

Details and patient eligibility

About

The goal of the project is to study the risk of coccidioidomycosis (valley fever) in patients receiving anti-TNF and other biologic agents for inflammatory arthritis in Tucson, Arizona.

Full description

Retrospective chart review of all patients with an inflammatory arthritis seen at the University Rheumatology clinic since January 2000.

Enrollment: 598 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• All active patients with an inflammatory arthritis seen at the University of Arizona from January 2000

Exclusion criteria

• None

Trial design

598 participants in 2 patient groups

Biologics

Description:

Patients receiving TNF inhibitors or biologic agents

DMARD

Description:

Patients receiving methotrexate without any biologic